These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6901713)

  • 1. Hyperuricosuria in cystic fibrosis patients treated with pancreatic enzyme supplements. A study of 16 patients in Israel.
    Sack J; Blau H; Goldfarb D; Ben-Zaray S; Katznelson D
    Isr J Med Sci; 1980 Jun; 16(6):417-9. PubMed ID: 6901713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperuricosuria due to high-dose pancreatic extract therapy in cystic fibrosis.
    Stapleton FB; Kennedy J; Nousia-Arvanitakis S; Linshaw MA
    N Engl J Med; 1976 Jul; 295(5):246-8. PubMed ID: 934188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis.
    FitzSimmons SC; Burkhart GA; Borowitz D; Grand RJ; Hammerstrom T; Durie PR; Lloyd-Still JD; Lowenfels AB
    N Engl J Med; 1997 May; 336(18):1283-9. PubMed ID: 9113931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of 2 pancreatic enzyme preparations in the treatment of digestive insufficiency in mucoviscidosis (cystic fibrosis)].
    Gottschalk B; Wiesemann HG; Stephan U
    Monatsschr Kinderheilkd; 1988 Sep; 136(9):626-9. PubMed ID: 3237230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uric acid serum concentrations in CF-children after pancreatic enzyme supplementation.
    Wiersbitzky S; Ballke EH; Wolf E; Paul W
    Padiatr Grenzgeb; 1989; 28(3):171-3. PubMed ID: 2761994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic approach to pancreatic extract-induced hyperuricosuria in cystic fibrosis.
    Nouisa-Arvanitakis S; Stapleton FB; Linshaw MA; Kennedy J
    J Pediatr; 1977 Feb; 90(2):302-5. PubMed ID: 830926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the cause of hyperuricosuria in cystic fibrosis patients.
    Niessen KH; Wolf A
    J Pediatr Gastroenterol Nutr; 1982; 1(3):349-54. PubMed ID: 6926538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sodium excretion in children with lithogenic disorders].
    Kovacević L; Kovacević S; Smoljanić Z; Peco-Antić A; Kostić N; Gajić M; Kovacević N; Jovanović O
    Srp Arh Celok Lek; 1998; 126(9-10):321-6. PubMed ID: 9863402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative study of the effect of kreon and cotazyme forte in children with cystic fibrosis].
    Zsíros J; Sólyom E
    Orv Hetil; 1988 May; 129(19):995-9. PubMed ID: 3290773
    [No Abstract]   [Full Text] [Related]  

  • 10. Factors increasing the risk for stone formation in adult patients with cystic fibrosis.
    Terribile M; Capuano M; Cangiano G; Carnovale V; Ferrara P; Petrarulo M; Marangella M
    Nephrol Dial Transplant; 2006 Jul; 21(7):1870-5. PubMed ID: 16595587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cimetidine and pancreatic enzymes on serum and fecal bile acids and fat absorption in cystic fibrosis.
    Boyle BJ; Long WB; Balistreri WF; Widzer SJ; Huang N
    Gastroenterology; 1980 May; 78(5 Pt 1):950-3. PubMed ID: 7380201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a risk for kidney stone formation in cystic fibrosis?
    Böhles H; Michalk D
    Helv Paediatr Acta; 1982 Jun; 37(3):267-72. PubMed ID: 7118558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Uric acid metabolism in children with hyperuricosuria].
    Gadomska-Prokop K; Konopielko Z
    Pol Merkur Lekarski; 2000 Apr; 8(46):177-8. PubMed ID: 10897600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of malabsorption in cystic fibrosis: influence of recent developments on clinical practice.
    Littlewood JM
    Postgrad Med J; 1996 Mar; 72 Suppl 2():S56-62; discussion S59-62. PubMed ID: 8869184
    [No Abstract]   [Full Text] [Related]  

  • 15. Direct assessment of gastrointestinal inflammation and mucosal immunity in children with cystic fibrosis.
    Croft NM; Marshall TG; Ferguson A
    Postgrad Med J; 1996 Mar; 72 Suppl 2():S32-6. PubMed ID: 8869180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of distal intestinal obstruction syndrome in cystic fibrosis.
    Rosenstein BJ; Langbaum TS
    J Pediatr Gastroenterol Nutr; 1983 May; 2(2):299-301. PubMed ID: 6553601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring pancreatin supplementation in cystic fibrosis patients with the 13C-Hiolein breath test: evidence for normalized fat assimilation with high dose pancreatin therapy.
    Braden B; Picard H; Caspary WF; Posselt HG; Lembcke B
    Z Gastroenterol; 1997 Feb; 35(2):123-9. PubMed ID: 9066102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts: pancreatic extracts.
    Littman A; Hanscom DH
    N Engl J Med; 1969 Jul; 281(4):201-4. PubMed ID: 4892805
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients.
    Caspi D; Lubart E; Graff E; Habot B; Yaron M; Segal R
    Arthritis Rheum; 2000 Jan; 43(1):103-8. PubMed ID: 10643705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical trial of several preparation types of the pancreatic extract Pancrex V in the treatment of cystic fibrosis].
    Braggion C; Mastella G
    Minerva Pediatr; 1985 Nov; 37(21-22):891-6. PubMed ID: 3912659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.